Nexvet Provides Update on NV-01 Program DUBLIN, Ireland and

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Nexvet Provides Update on NV-01 Program

DUBLIN, Ireland and MELBOURNE, Australia, April 15, 2015 (GLOBE NEWSWIRE) -- Nexvet Biopharma (Nasdaq: NVET ), a veterinary biologic therapy developer, announced today an update on its development program for NV-01, an anti-nerve growth factor (NGF) monoclonal antibody (mAb) for the control of pain associated with canine osteoarthritis.

Following the results of the NV-01 pivotal field safety and efficacy study sample size reassessment (SSR) announced on March 9, 2015, Nexvet has assessed the impact of time, cost, and related logistical issues regarding the feasibility of substantially increasing the number of dogs in the current study, or initiating additional studies. This assessment included consulting with both the United States Food and Drug Administration's Center for Veterinary Medicine (CVM) and Virbac, the Company's distribution partner outside of the United States and Canada. The key conclusions from this assessment are:

1.    The current study will continue to completion without a change in study size, and is on-target to be completed by December 2015. The study remains blinded. The SSR indicated this study has a low probability of achieving the primary endpoint designated for U.S. regulatory approval (a statistically significant change in Client Specific Outcome Measures score between enrolment and day 28) without a substantial increase in the current size of the study. However, there are a number of secondary endpoints measured in the study which will benefit further studies of NV-01, and potentially support registration outside the United States.

2.    A new placebo-controlled multi-site field safety and efficacy study will shortly commence assessing various doses and dosing regimens of NV-01. This new study is expected to enrol approximately 150 dogs, cost approximately $1.0 million, and provide valuable information that may assist the design of a future pivotal study. Rather than substantially increasing the size of the current study, Nexvet believes that resources are better spent on additional in-field studies gathering alternative information. The target completion date of this new study is the fourth quarter of 2015.

3.    Nexvet is deferring various program costs associated with NV-01 until the completion of both the current NV-01 pivotal safety and efficacy study and the new study.

4.    Nexvet and Virbac remain strongly committed to the potential of NV-01 as a novel veterinary biopharmaceutical for the control of chronic pain associated with osteoarthritis in dogs.

"By taking a forward-looking approach and employing the SSR, we created an early opportunity to review our strategy, reassess associated expenditures, and rapidly commence additional studies. The new multi-center field study will enable the evaluation of alternative doses and treatment regimens and allow us to evaluate alternative endpoints to optimize NV-01's clinical assessment," commented Dr. Mark Heffernan, Chief Executive Officer of Nexvet.

"Late-stage clinical trials assessing anti-NGF mAbs for the control of pain associated with chronic osteoarthritis in humans have recently resumed. We believe the biology supporting this approach is well-substantiated and our previous studies with NV-01 in dogs are strongly supportive. We remain committed to this unique approach for chronic pain management in dogs, and we are pleased that our parallel approach in cats, the NV-02 program, remains on track to complete its proof-of-concept study by mid-2015," concluded Dr. Heffernan.

About the sample size reassessment (SSR)

An SSR is a statistical tool designed to assess whether the target study size of an active clinical study is likely to meet the study's primary endpoint or whether additional patients are required. It also addresses futility criteria (which assess whether the investigational product is capable of demonstrating a positive effect). The SSR for NV-01's pivotal safety and efficacy study was conducted by an independent statistician when 67% of the study's participants had reached the 28-day primary endpoint.

Although NV-01 did not meet the futility criteria set for the study, the SSR did indicate that, in order to have a high probability of a statistically significant endpoint at the day 28 primary assessment, it would be necessary to substantially increase the current size of the study.

About Nexvet ( www.nexvet.com )

Nexvet is a clinical-stage biopharmaceutical company focused on transforming the therapeutic market for companion animals, such as dogs and cats, by developing and commercializing novel, species-specific biologics. Nexvet's proprietary PETization™ platform is designed to rapidly create monoclonal antibodies ("mAbs") that are recognized as "self" or "native" by an animal's immune system, a property Nexvet refers to as "100% species-specificity." Nexvet's product candidates also build upon the safety and efficacy data from clinically tested human therapies, thereby reducing clinical risk and development cost.

Forward-Looking Statements

All statements in this press release other than statements of historical fact are forward-looking statements, including statements regarding our ability to reach a statistically significant endpoint at the primary assessment of the NV-01 pivotal field safety and efficacy study, the results of the current, new or any future NV-01 study, future expenditures relating to NV-01, the time for completion of any of our studies, our future results of operations and financial position, business strategy, prospective products, product approvals, research and development costs, timing and likelihood of success, plans and objectives of management for future operations, and future results of current and anticipated products. These statements relate to future events or to our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to materially differ from the results, performance or achievements expressed or implied by the forward-looking statements.  The words "anticipate," "continue," "expect," "may," "objective," "plan," "potential," "position," "target," "will" or similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these words.  These forward-looking statements are based on current expectations, estimates, forecasts and projections about our business and the industry in which we operate, and management's beliefs and assumptions are not guarantees of future results, performance or achievements. Factors that could cause actual results, performance or achievements to differ materially include those summarized under Risk Factors in our reports on Forms 10-Q and 10-K and the other documents we file from time to time with the Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements. We undertake no obligation to revise or update these forward-looking statements, except as required by law.

Further information: Investors Candice Knoll Blueprint Life Science Group +1 415-375-3340 Ext. 105 Media Lynn Granito Berry & Company Public Relations +1 212-253-8881

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 201

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading
Newegg’s GIGABYTE Event Is Brand Work, Not a Catalyst

Updated Category News Views 311

A 2,300-square-foot room can tell a retailer plenty about its tribe. On November 21, Newegg is turning its Diamond Bar Gamer Zone into the home base for GIGABYTE’s AORUS VS40 celebration, a free five-hour event marking the hardware maker’s 40th anniversary. There will be 1v1 VALORANT and League of Legends contests, demo stations, raffles, anniversary merchandise, food...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 274

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
PettiChat’s Digital Pet Twin Has Real Consumer Pull

Updated Category News Views 173

A Collar Gadget Is Chasing the Empty-House Problem Leave a dog or cat alone for a few hours and plenty of owners turn into amateur detectives. Did the cat eat? Has the dog been pacing? Why was that one weird noise caught on the home camera? Seattle startup PettiChat is trying to turn that itch into a product category with PettiLive!, a screen-based version of a pet that...

Continue Reading
Human Frontier Mission Puts AI Research on Display

Updated Category News Views 162

A laboratory notebook is about to become the real product in this AI experiment. Human Frontier Mission, or HFM, says it will launch globally on Nov. 24, opening a research program where domain specialists frame scientific and engineering problems while autonomous AI agents develop and test possible answers. The unusual bit is not merely handing models difficult work. It...

Continue Reading
Ajman Memory Gives Heritage a Durable Digital Backbone

Updated Category News Views 138

Archives usually get applause only after somebody realizes a piece of history has vanished. Ajman is trying to skip that miserable part. During the Ajman Media Forum 2026, held November 18 and 19 at the Emirates Hospitality Centre, the emirate launched Ajman Memory, a project built to collect, document and preserve photographs, papers and video recording its development....

Continue Reading
Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 411

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading
D-Wave Investors Face a December 15 Lead Plaintiff Clock

Updated Category News Views 252

August Put the Story Under a Harsh Light Two ugly August trading sessions are doing a lot of work in the case now confronting D-Wave Quantum. The company sits in a field that attracts big dreams, big headlines, and, frankly, plenty of investor imagination. But imagination does not cushion a portfolio when expectations crack. The lawsuits concern people who bought or...

Continue Reading
PHONO's 150 MW RE+ Win Tests Its U.S. Solar Staying Power

Updated Category News Views 237

A trade-show order book is not cash in the bank, but 150 MW is still a number worth circling in red. PHONO used RE+ 2026 in Las Vegas, held November 17 through 19, to celebrate 20 years in business, parade its solar and storage lineup, and announce new U.S. orders. In a solar market that has become touchier about provenance, compliance and delivered economics, the company...

Continue Reading
WaterField’s Nova Case Bets on Better Handheld Carry

Updated Category News Views 308

Tiny handhelds have spawned a surprisingly fussy luggage problem: protection without the clown-show aesthetic. WaterField Designs is taking a clean swing at that with a custom case for the Retroid Pocket Nova, a sleeve-like carrier built around the device rather than some generic pouch that leaves everything rattling around inside. This is not a market-moving corporate...

Continue Reading

Top 5 Most Recently Viewed Articles

UFP Industries Earnings Preview: What to Expect This Quarter

Updated Category News Views 165

UFP Industries Earnings Preview: What to Expect This Quarter UFP Industries (NASDAQ: UFPI) is gearing up for its upcoming quarterly earnings report. Investors are eager to learn about the financial health and performance of this leading supplier. Analysts project that UFP Industries will report earnings per share (EPS) of $1.86 in its upcoming announcement. Investors'...

Continue Reading
Fosun Highlights Innovations at CIIE Amid Global Opportunities

Updated Category News Views 101

Fosun Showcases Innovations at CIIE On November 5, the China International Import Expo (CIIE) commenced, marking a significant event for Fosun as a seven-time participant. This year's exhibition highlighted the company's commitment to innovation in healthcare, with impressive displays at its Fosun Pharma booth. Attendees were introduced to advanced medical devices and...

Continue Reading
Innovative DC Power Supplies Enhance Panasonic TOUGHBOOKs

Updated Category News Views 146

Introducing Havis DC Power Supplies for Mobile Workspaces Havis, Inc. has taken a significant step forward in rugged mobility solutions with the launch of their latest line of DC Power Supplies specifically designed for Panasonic TOUGHBOOK devices. These power supplies are essential for professionals who depend on reliability in challenging conditions. Why Choose Havis DC...

Continue Reading
Nvidia and UAE Collaboration: A New Era in AI Exports

Updated Category News Views 194

Nvidia's Stock Surge Following UAE AI Export Approval Nvidia (NASDAQ: NVDA) witnessed a remarkable rise in its stock value recently after the U.S. government greenlit billions in chip exports to the United Arab Emirates (UAE). This event is a significant milestone, marking the beginning of a collaboration focused on artificial intelligence and technology advancement. The...

Continue Reading
How Fed Decisions and Tech Sector Gains Shape Markets

Updated Category Markets Views 412

Surprising CPI data indicating a 3.3% increase in May led the Federal Reserve to maintain interest rates unchanged. The IT industry, meantime, soared, with Oracle seeing a big boost despite missing earnings estimates because of strong demand for its cloud services and Apple's stock rising because of new AI features. These developments point to robust investment prospects...

Continue Reading